Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

NCT03604991 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03604991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03604991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Suspended
Start date
May 3, 2019
Completion date
March 31, 2027
Enrollment
278 (estimated)
Sites
488

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage ii esophageal adenocarcinoma ajcc v8, clinical stage ii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva esophageal adenocarcinoma ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma